Seres Therapeutics has reported promising findings from its Phase 1b placebo-controlled trial evaluating SER-155 in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The study demonstrated that SER-155 administration was significantly associated with a reduction in bacterial bloodstream infections (BSIs), systemic antibiotic exposure, and febrile neutropenia incidence compared to placebo through day 100 post-transplant.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a pivotal treatment for various hematological malignancies. However, it is frequently accompanied by severe complications, including infections, due to the immunocompromised state of patients. Antimicrobial prophylaxis remains a crucial component of post-transplant care. SER-155, a novel microbiome therapeutic developed by Seres Therapeutics, aims to restore gut microbiota diversity and may enhance immune function, thereby potentially reducing infectious complications.
Methods’
The Phase 1b study was designed as a placebo-controlled trial to assess the safety and efficacy of SER-155 in patients undergoing allo-HSCT. Participants were randomly assigned to receive either SER-155 or placebo. Key outcomes measured included the incidence of bacterial bloodstream infections (BSIs), systemic antibiotic exposure, and febrile neutropenia up to day 100 post-transplant. Safety assessments included adverse events and laboratory parameters.
Results’
The administration of SER-155 was associated with a significant reduction in the incidence of BSIs compared to the placebo group. Furthermore, patients receiving SER-155 exhibited a decrease in systemic antibiotic exposure, suggesting a lower burden of infection during the critical post-transplant period. Additionally, the incidence of febrile neutropenia was notably lower in the SER-155 cohort.
Adverse events were monitored throughout the study, with SER-155 demonstrating a favorable safety profile. No significant differences in the rates of serious adverse events were noted between the treatment and placebo groups.
Discussion’
The results of this Phase 1b study provide encouraging evidence that SER-155 may contribute to improved clinical outcomes following allo-HSCT, particularly in the context of infectious complications. The reduction in BSIs and overall antibiotic use indicates a potential therapeutic role for SER-155 in enhancing patient recovery and mitigating the risks associated with the immunocompromised state.
The findings align with the increasing recognition of the gut microbiome’s impact on immune modulation and infection susceptibility. Further studies are warranted to explore the long-term effects of SER-155 and its potential utility as part of the standard postoperative care regimen in allo-HSCT patients.
Conclusion’
SER-155 administration in patients undergoing allo-HSCT was associated with a significant reduction in bacterial infections, decreased need for antibiotics, and lower rates of febrile neutropenia compared to placebo. The promising safety profile further underscores the need for continued investigation into SER-155’s role in post-transplant care.
Financial Disclosure’
As of the date of this report, Seres Therapeutics Inc. holds approximately 128.29 million shares outstanding, with a current trading price of $0.96. This financial context may influence future developments and studies related to SER-155 and other therapeutic interventions in this evolving field.
References’
- Seres Therapeutics, Inc. (Date). Company Press Release.
- Additional relevant literature on allo-HSCT and microbiome therapies
Comments